Liping Yan

Liping Yan

Auto-generated profile, based on publicly available information

Liping Yan

Department of Breast Surgery, Jiangxi Maternal and Child Health Hospital, Nanchang, PR China; Key Laboratory of High Incidence Tumor Prevention and Treatment Guangxi Medical University, Nanning, PR China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Biochemical Pharmacology
Verified
Journal Article
Open access
LYLiping Yan
Liping Yan
QTQi-xing Tan
Qi-xing Tan
JZJia Zhu
Jia Zhu
YHYongfei He
Yongfei He
TPTao Peng
Tao Peng
JHJianxin He
Jianxin He
Breast cancer liver metastasis presents a significant clinical challenge, requiring a deeper understanding of its underlying mechanisms. In this study, we explored the role of serum metabolites and gut microbiota in breast cancer liver metastasis, with a particular focus on the effects of glycochenodeoxycholic acid sodium salt (GCDC). Serum metabolites were analyzed using liquid chromatography-mass spectrometry (LC-MS), while gut microbiota composition was assessed through 16S rDNA sequencing of stool samples. Statistical analyses revealed a strong correlation between gut microbiota and GCDC levels, which varied markedly among breast cancer, breast cancer liver metastasis, and healthy control groups. GCDC was identified as a microbiota-related metabolite through high-throughput bioinformatics screening. In vitro experiments showed that GCDC inhibited breast cancer cell proliferation, migration, and invasion while inducing cell death. In vivo, GCDC treatment reduced subcutaneous tumor growth and prevented liver metastases, as evidenced by decreased Ki67 expression in tumor tissues. These findings suggested that GCDC suppresses breast cancer liver metastasis by inhibiting cancer cell growth and migration, underscoring its potential as a biomarker for early detection and a therapeutic agent for liver metastasis in patients with breast cancer. Further research is needed to clarify its mechanisms and explore its clinical applications.

28 September 2024 in Heliyon
Verified
Journal Article
Open access
LYLiping Yan
Liping Yan
YCYuexia Chen
Yuexia Chen
JHJianxin He
Jianxin He
A non-invasive predictive model was developed using radiomic features to forecast CXCL9 expression level in breast cancer patients. CXCL9 expression data and MRI images of breast cancer patients were obtained from The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA) databases, respectively. Local tissue samples from 20 breast cancer patients were collected to measure CXCL9 expression levels. Radiomic features were extracted from MRI images using 3DSlicer, and the minimum Redundancy Maximum Relevance and Recursive Feature Elimination (mRMR_RFE) method was employed to select the most pertinent radiomic features associated with CXCL9 expression levels. Support vector machine (SVM) and Logistic Regression (LR) models were utilized to construct the predictive model, and the area under the receiver operating characteristic curve (AUC) was calculated for performance evaluation. CXCL9 was found to be upregulated in breast cancer patients and linked to breast cancer prognosis. Nine radiomic features were ultimately selected using the mRMR_RFE method, and SVM and LR models were trained and validated. The SVM model achieved AUC values of 0.748 and 0.711 in the training and validation sets, respectively. The LR model obtained AUC values of 0.771 and 0.724 in the training and validation sets, respectively. The utilization of MRI radiomic features for predicting CXCL9 expression level provides a novel non-invasive approach for breast cancer Prognostic research.